Reclast contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption.
Reclast (zoledronic acid) is indicated for the following:
Reclast is indicated for treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, Reclast reduces the incidence of fractures (hip, vertebral and non-vertebral osteoporosis-related fractures) [ see Clinical Studies (14 .1)].
Paget's Disease of Bone
Reclast is indicated for treatment of Paget's disease of bone in men and women. Treatment is indicated in patients with Paget’s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [ see Clinical Studies (14 . 2 ) ].
Media Articles Related to Reclast (Zoledronic Acid)
Zoledronic Acid Ups BMD in Seniors Without Cutting Fractures
Source: Medscape Orthopaedics Headlines [2015.04.15]
A single infusion of zoledronic acid improved BMD over the course of 2 years in frail institutionalized elderly women with osteoporosis, but this improvement did not translate to better outcomes.
Medscape Medical News
Bone mineral density improved in frail elderly women treated with zoledronic acid
Source: Bones / Orthopedics News From Medical News Today [2015.04.14]
A single intravenous dose of the osteoporosis drug zoledronic acid improved bone mineral density in a group of frail elderly women living in nursing homes and long-term-care facilities, according...
Published Studies Related to Reclast (Zoledronic Acid)
Delaying skeletal-related events in a randomized phase 3 study of denosumab
versus zoledronic acid in patients with advanced cancer: an analysis of data from
patients with solid tumors. 
myeloma... CONCLUSIONS: Denosumab was more effective in delaying or preventing SREs in
Reduction in the risk of clinical fractures after a single dose of zoledronic
Acid 5 milligrams. 
1 infusion of zoledronic acid... CONCLUSIONS: In this post hoc analysis based on postrandomization subgroups,
Clinical significance of zoledronic acid and strontium-89 in patients with
asymptomatic bone metastases from non-small-cell lung cancer. 
lung cancer (NSCLC) with asymptomatic bone metastases (BMs)... CONCLUSIONS: Treatment with ZA and/or Sr-89 significantly extended the time to
Fracture risk and zoledronic acid therapy in men with osteoporosis. 
osteoporosis... CONCLUSIONS: Zoledronic acid treatment was associated with a significantly
Superiority of denosumab to zoledronic acid for prevention of skeletal-related
events: a combined analysis of 3 pivotal, randomised, phase 3 trials. 
across three pivotal studies... CONCLUSION: Denosumab was superior to zoledronic acid in preventing SRE with
Clinical Trials Related to Reclast (Zoledronic Acid)
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer [Recruiting]
The overall purpose of this research is to evaluate the safety and side effects of
zoledronic acid (also known as Zometa) in patients before they have surgery to remove the
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year [Recruiting]
The primary objective of this study is to investigate the repeat-dose pharmacokinetic (PK)
profile of zoledronic acid when administered every 4 weeks versus every 12 weeks, in
patients treated with 9-20 infusions of zoledronic acid during the previous 10-15 months.
Re-treatment of Patients With Paget's Disease Using Zoledronic Acid [Recruiting]
The purpose of this study is to demonstrate that patients with Paget's disease of the bone
who had responded to zoledronic acid treatment as participants in the core registration
studies CZOL446K2304 and CZOL446K2305 and later experienced a relapse can be successfully
treated with a 5mg infusion of zoledronic acid.
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer [Recruiting]
The primary goal for this trial is to assess the change in PET scans with the administration
of zoledronate (bisphosphonate) therapy in patients with metastatic prostate cancer. It
has been established that zoledronate therapy may play a role in delaying and reducing the
incidence of skeletal events. Researchers propose to evaluate the change in the uptake
value of FMAU PET scan after the zoledronate therapy. It has been demonstrated that FMAU
PET scans can successfully demonstrate and detect bony metastatic sites in prostate cancer.
In addition, investigators would like to evaluate the change in the level of the
prostate-specific antigen (PSA) in the patient as well as outcome of bone scans.
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients [Recruiting]
This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell
(CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone
Reports of Suspected Reclast (Zoledronic Acid) Side Effects
Femur Fracture (154),
Pain in Extremity (133),
Myalgia (113), more >>